

**Secretome of senescent hepatic stellate cells favors malignant
transformation from nonalcoholic steatohepatitis-fibrotic progression
to hepatocellular carcinoma**

Yuan Zhou¹, Li Zhang¹, Yue Ma¹, Li Xie¹, Yong-yu Yang¹, Cheng Jin¹,
Hui Chen¹, Ying Zhou³, Jia Ding², Guang-qi Song³, Jian Wu^{1,4,5}

¹Department of Medical Microbiology & Parasitology, MOE/NHC/CAMS Key
Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan
University, Shanghai 200032, China

²Department of Gastroenterology, Shanghai Jing'an District Central Hospital, Fudan
University, Shanghai 200040, China;

³Joint Laboratory of Biomaterials and Translational Medicine, Puheng Technology
Co., Ltd, Suzhou 215163, China

⁴Department of Gastroenterology & Hepatology, Zhongshan Hospital, Fudan
University, Shanghai 200032, China

⁵Shanghai Institute of Liver Diseases, Fudan University Shanghai Medical College,
Shanghai 200032, China

CORRESPONDING AUTHORS:

Jian Wu, MD, PhD, FAASLD

Department of Medical Microbiology, Key Laboratory of Medical Molecular
Virology, School of Basic Medical Sciences
Fudan University Shanghai Medical College
138 Yixue Yuan Road, P. O. Box 228,
Shanghai 200032, China
Tel: +86(21)5423-7705
Fax: +86(21)6422-7201
Email: jian.wu@fudan.edu.cn
ORCID: 0000-0001-9933-7364

Guang-qi Song, PhD

Joint Laboratory of Biomaterials and Translational Medicine
Puheng Technology Co., Ltd
Suzhou 215000, China
song.guangqi@zs-hospital.sh.cn
ORCID: 0000-0002-2409-0771

Jia Ding, MD, PhD

Department of Gastroenterology
Shanghai Jing'an District Central Hospital,
Fudan University
Shanghai 200040, China
Email: jiading12@fudan.edu.cn
ORCID: 0000-0002-7391-8520

SUPPLEMENTARY MATERIALS

SUPPLEMENTARY FIGURES

Figure S1




Figure S1 Progression from NASH, fibrosis to HCC in HFCD-HF/G-fed mice at 14 months. (A) Photographs of a liver tumor nodule at 14 months. (B) Representative micrographs of H&E staining of tumor nodular tissues. Image was taken at original magnification (20×). Scale bars = 1 mm. (C) Representative micrographs of H&E staining of tumor nodular tissues. Image was taken at original magnification (400×). Scale bars = 50 μm. Representative micrographs of immunohistochemical staining of (D) AFP and (E) c-Myc in tumor tissues of HFCD-HF/G diet-fed mice for 14 months. Images were taken at original magnification (400×). Scale bars = 50 μm.

Figure S2




Figure S2 Representative micrographs of p16 and p21 immunofluorescent staining of liver sections from mice NASH-HCC model. (A) Representative micrographs of counter-staining of p16 (red) or (B) p21 (red) with α -SMA (green) HSCs of liver tissues

at 2, 5, 9, 12 and 14 months in the control diet or HFCD-HF/G diet-fed mice. Images were taken at original magnification (630 \times). Scale bars = 50 μ m.

Figure S3




Figure S3 Positivity of p16 and p21 in ETP-treated or 30-passage-induced senescent HSCs. (A) Representative micrographs of fluorescent staining of p16 or p21 positivity in ETP-treated and F30 senescent HSCs. Nuclear location of p16 or p21 was stained in red with counter-staining of nuclei with DAPI. Images were taken at original magnification (200 \times). Scale bars = 50 μ m.

Figure S4




Figure S4 Activation of β -catenin in HCC tissue and mouse primary hepatocytes. Representative micrographs of (A) immunofluorescent staining and (B) immunohistochemical staining of β -catenin in tumor tissues of HFCD-HF/G diet-fed mice for 14 months. Immunofluorescent staining images were taken at original magnification (630 \times). Immunohistochemical staining images were taken at original magnification (400 \times). Scale bars = 50 μ m. (C) Representative micrographs of immunofluorescent staining of β -catenin in mouse primary hepatocytes treated with growing and senescent HSC (F30-HSC) medium supernatant. Images were taken at original magnification (630 \times). Scale bars = 50 μ m.

SUPPLEMENTARY TABLES

Table S1 Primers used in qRT-PCR

Sequences of mouse primers used in qRT-PCR

| Genes | Forward Primer | Reverse Primer |
|------------------|-----------------------|-----------------------|
| c-Myc | TTGGAAACCCCGCAGACAG | TCTCTCCTCGTCGCAGATG |
| Oct-4 | TGGGCTAGAGAAGGATGTGGT | GGAAAGGTGTCCCTGTAGCC |
| KLF-4 | TGGGGGTTTTGGTTTGAGGT | ACTGGTGCTGAGCCCTGAATC |
| Sox-2 | AGGAAAGGGTCTTGCTGGG | ACGAAAACGGTCTTGCCAGT |
| E-cadherin | AACCCAAGCACGTATCAGGG | ACTGCTGGTCAGGATCGTTG |
| N-cadherin | GGCCTTGCTTCAGGCGT | CATTGAGAAGGGGCTGTCCT |
| Vimentin | TTTGCTGACCTCTCTGAGGC | CTCCAGGGACTCGTTAGTGC |
| β -catenin | GTCAGTGCAGGAGGCCGA | CTCCATCAGGTCAGCTTGAGT |
| Gli-1 | CCATTGGTACCATGAGCCCT | AGCATCATTGAACCCCGAGT |
| β -actin | GTCAGAAGGACTCCTATGTG | ACGCAGCTCATTGTAGAAG |

Sequences of rat primers used in qRT-PCR

| Genes | Forward Primer | Reverse Primer |
|------------------|--------------------------|---------------------------|
| TGF- β 1 | AGGAGACGGAATACAGGGCT | ACGTTTGGGACTGATCCCATT |
| CTGF | GCGCCTGTTCTAAGACCTGT | TGCACTTTTTGCCCCTTCTTAATGT |
| TIMP1 | CCTCTGGCATCCTCTTGTTG | GGGAACCCATGAATTTAGCC |
| Procoll-I | GGAAGCGAAGGTTCCGAATC | GCTGTTCTTGCAGTGATAGGTGA |
| Procollagen III | GCCTACATGGATCAGGCCAA | CACCAGTGTGTTTAGTGCAGC |
| Procollagen IV | CCCAAAGGCATCAGGGGAAT | ATCCTGGTAAACCAGCCAGC |
| Fibronectin | CCACCATCACTGGTCTGGAG | GGGTGTGGAAGGGTAACCAG |
| MMP3 | CCTCGTGGTACCCACCAAAT | TTTCGCCAAAAGTGCCTGTC |
| MMP10 | CAATCCCTGTATGGAGCCCG | TCTCAGCATGGTGACTGCAT |
| MMP12 | ACCAGAGCCACACTATCCCA | CTGCCTCACATCGTACCTCC |
| IL-6 | AAGTCCGGAGAGGAGACTTCA | TTGCCATTGCACAACCTCTTTT |
| IL-1 β | TCTGTGACTCGTGGGATGAT | TTGTTGTTTCATCTCGAAGCC |
| CXCL1 | TGCACCCAAACCGAAGTCAT | ACTTGGGGACACCCTTTAGC |
| CXCL9 | CACTGTGGAGTTCGAGGAACC | GTTAGGGCTTGGGGCAAACCT |
| Gli-1 | AACTCCACGAGCACACAGG | TACTCAGCACCAGCATCACC |
| PTCH | GGGGCTCCGGGAAATTAATAAAAG | CCAGTAGCCTTCCCCATAGCC |
| Cyclin D1 | GTGCCATCCATGCGGAA | GGATGGTCTGCTTGTCTC |
| BCL-2 | GTCATGTGTGTGGAGAGCGT | ACAGTTCACAAAGGCATCC |
| β -catenin | GAAAATGCTTGGGTCGCCAG | CATTTTCTGCAGCCCACCAG |
| β -actin | AGCTGTGCTATGTTGCCCTA | GAACCGCTCATTGCCGATAG |

Table S2 Commercial sources for antibodies used in immunofluorescent staining

| Antibody | Company | Species | Catalogue # |
|------------------|-------------|---------|-------------|
| α -SMA | CST | Rabbit | 19245 |
| α -SMA | Proteintech | Mouse | 67735-1-Ig |
| Gli-1 | Proteintech | Mouse | 66905-1-Ig |
| Ki67 | Servicebio | Rabbit | GB111141 |
| Albumin | Abgent | Rabbit | P02768 |
| AFP | Proteintech | Rabbit | 14550-1-AP |
| β -catenin | Abmart | Mouse | M24002M |
| β -catenin | Abclonal | Rabbit | A19657 |
| E-cadherin | Abclonal | Rabbit | A22850 |
| c-Myc | Abways | Rabbit | CY5150 |
| p16 | Proteintech | Rabbit | 10883-1-AP |
| p21 | Proteintech | Rabbit | 10355-1-AP |
| HNF4 α | Abcam | Mouse | ab41898 |

Table S3 Commercial sources for ELISA kits used for determination of protein concentration in culture medium

| Protein | Company | Species | Catalogue # |
|----------------|-------------|---------|-------------|
| TGF- β 1 | Abclonal | Rat | RK00059 |
| CTGF | Abcam | Rat | ab275897 |
| PDGF-BB | Elabscience | Rat | E-EL-R0537c |
| IGF1 | Abclonal | Rat | RK03737 |
| Wnt10b | Novus | Rat | NBP3-00485 |
| Shh-N | R&D | Rat | DSHH00 |

Table S4 SASP capable of interacting with hepatocytes to induce malignant transformation.

| Protein name | Gene name | Function according to reference |
|---|-----------|---|
| Sperm-associated antigen 9 | Spag9 | Aberrant expression promotes HCC tumorigenesis via JNK pathway [1] |
| Major vault protein | Mvp | Promote HDM2-dependent loss of p53 for HCC development [2] |
| Flap endonuclease 1 | Fen1 | Promote HCC through enhanced USP7/MDM2-mediated P53 inactivation [3] |
| Peroxiredoxin-4 | Prdx4 | Promote tumorigenesis and metastasis via β -catenin pathway [4] |
| Ribose-5-phosphate isomerase | Rpia | Promote HCC via PP2A and ERK signaling [5] |
| Bromodomain-containing protein 2 | Brd2 | Promote HCC via Wnt/ β -catenin pathway [6] |
| Mitochondrial fission 1 protein | Fis1 | Promote autophagy and HCC cells survival via NFKB and TP53 pathway ROS regulation [7] |
| Fatty acid-binding protein 5 | Fabp5 | Promote tumor angiogenesis and activation of IL6 / STAT3 / VEGFA pathway in HCC [8] |
| Protein transport protein Sec61 subunit alpha isoform 1 | Sec61a1 | Promote cell proliferation and migration [9] |
| Proteasome activator subunit 4 | Psme4 | Promote the development of HCC via mTOR signaling pathway [10] |
| C-terminal-binding protein 1 | Ctbp1 | Play a key role in hypoxia-induced EMT and sarcomatoid transformation [11] Promote cell proliferation in HCC by regulating miR-623/cell cycle protein D1 axis [12] |

REFERENCES

1. Lou G, Dong X, Xia C, Ye B, Yan Q, Wu S, et al. Direct targeting sperm-associated antigen 9 by miR-141 influences hepatocellular carcinoma cell growth and metastasis via JNK pathway. *J Exp Clin Cancer Res.* 2016; 35: 14.
2. Yu H, Li M, He R, Fang P, Wang Q, Yi Y, et al. Major Vault Protein Promotes Hepatocellular Carcinoma Through Targeting Interferon Regulatory Factor 2 and Decreasing p53 Activity. *Hepatology.* 2020; 72: 518-34.
3. Bian S, Ni W, Zhu M, Zhang X, Qiang Y, Zhang J, et al. Flap endonuclease 1 Facilitated Hepatocellular Carcinoma Progression by Enhancing USP7/MDM2-mediated P53 Inactivation. *Int J Biol Sci.* 2022; 18: 1022-38.
4. Wang W, Shen XB, Huang DB, Jia W, Liu WB, He YF. Peroxiredoxin 4 suppresses anoikis and augments growth and metastasis of hepatocellular carcinoma cells through the beta-catenin/ID2 pathway. *Cell Oncol (Dordr).* 2019; 42: 769-81.
5. Ciou SC, Chou YT, Liu YL, Nieh YC, Lu JW, Huang SF, et al. Ribose-5-phosphate isomerase A regulates hepatocarcinogenesis via PP2A and ERK signaling. *Int J Cancer.* 2015; 137: 104-15.
6. Fang D, Wang MR, Guan JL, Han YY, Sheng JQ, Tian DA, et al. Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/beta-catenin signaling pathway. *Exp Cell Res.* 2021; 406: 112727.
7. Huang Q, Zhan L, Cao H, Li J, Lyu Y, Guo X, et al. Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways. *Autophagy.* 2016; 12: 999-1014.
8. Pan L, Xiao H, Liao R, Chen Q, Peng C, Zhang Y, et al. Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma. *Biomed Pharmacother.* 2018; 106: 68-76.
9. Fa X, Song P, Fu Y, Deng Y, Liu K. Long non-coding RNA VPS9D1-AS1 facilitates cell proliferation, migration and stemness in hepatocellular carcinoma. *Cancer Cell Int.* 2021; 21: 131.
10. Ge S, Huang H, Huang W, Ji R, Chen J, Wu S, et al. PSME4 Activates mTOR Signaling and Promotes the Malignant Progression of Hepatocellular Carcinoma. *Int J Gen Med.* 2022; 15: 885-95.
11. Zhang X, Wang X, Jia L, Yang Y, Yang F, Xiao S. CtBP1 Mediates Hypoxia-Induced Sarcomatoid Transformation in Hepatocellular Carcinoma. *J Hepatocell Carcinoma.* 2022; 9: 57-67.
12. Wang M, Zhao H. LncRNA CTBP1-AS2 Promotes Cell Proliferation in Hepatocellular Carcinoma by Regulating the miR-623/Cyclin D1 Axis. *Cancer Biother Radiopharm.* 2020; 35: 765-70.